Young Bae Lee Hansen: Recommendations on measurement units – why and how: eJIFCC Volume 30 no 3 – 2019
External Quality Assessment (EQA) and Alternative Assessment Procedures (AAP) in Molecular Diagnostics: Findings of an International Survey. Deborah A. Payne, Graciela Russomando, Mark W. Linder, Katarina Baluchova, Tester Ashavaid, Werner Steimer, Parviz Ahmad-Nejad, and the IFCC Committee for Molecular Diagnostics (C-MD) Approved by the SD. Now in submission process; probably CCA
The results of RELA2018 have been evaluated and published http://www.dgkl-rfb.de:81
1. “A multicenter assay to evaluate the harmonization of PINP assays: a report of the IOF IFCC Committee on Bone metabolism” accepted for publication in CCLM;
2. Abstract on “PINP harmonization: a report of the IOF-IFCC Committee for Bone metabolism” presented during IOF meeting in Paris on April 5th
Miller WG, Bachmann LM, Fleming JK, Delanghe JR, Parsa A, Narva AS. Recommendations for reporting low and high values for urinary albumin and total protein [Letter to the Editor]. Clin Chem 2019; 65(2):349-350.
The group aims for submission of the following manuscripts in 2020:
- A first manuscript will be a conceptual paper on standardization of multiple apolipoproteins with a common LC-MS approach, and will cover the clinical rationale and the unmet clinical needs for personalized and stratified cardiovascular risk assessment and treatment as well as the metrological striving for establishing SI-traceable multiplex apo test.
- By invitation: a special paper on apo(a) standardization will be written for the special issue of CCA.
- A third manuscript will be a technical note or letter on the improved digestion of apolipoproteins using a combination of lysC and trypsin. This manuscript will summarize the findings and evidence gathered by the three reference labs (LUMC, CDC and UKL).
- A fourth manuscript that will be in the preparation phase by the end of 2020 is the development of a harmonized LC-MS based reference method, including results from the planned ring trials.
Members of the group have participated in several related publications:
• Orsi FA, Lijfering WM, Van der Laarse A, Ruhaak LR, Rosendaal FR, Cannegieter SC, Cobbaert C. Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk. Clin Epidemiol. 2019 https://doi.org/ 10.2147/CLEP.S196266.
• Ruhaak LR, Van der Laarse A, Cobbaert CM. Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia. Annals of Clinical Biochemistry. 2019 https://doi.org/10.1177/0004563219827620
• Dittrich J, Beutner F, Teren A, Thiery J, Burkhardt R, Scholz M, Ceglarek U. Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease. Atherosclerosis. 2019 Feb;281:17-24. https://doi.org/10.1016/j. atherosclerosis.2018.11.006
What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? - Practical recommendations on pre-analytical issues by the IFCC workgroup cfDNA R. Danesi, Y. M. D. Lo, M. Oellerich, J. Beck, S. Galbiati, M. del Re, E. Lianidou, M. Neumaier, R.H.N. van Schaik – On behalf of the IFCC Working Group cfDNA (to be submitted to CCA)